Researchers out of the University of Alabama’s (UAB) Hugh Kaul Precision Medicine Institute played an instrumental role in identifying androgen deprivation therapy and hence the drug degarelix as a potential drug candidate to prevent SARS-CoV-2 virus from entering lung tissue and causing damage and a high risk of mortality. That drug has now entered a Phase II clinical trial sponsored by the U.S. Department of Veterans Affairs (VA) Office of Research and Development.
TrialSite News offers a brief overview of how some “medical detectives” at UAB helped uncover the possible reuse of an FDA-approved drug targeting COVID-19.
As the COVID-19 pandemic unleashed its initial deadly fury in China, by January the research team at UAB’s Precision Medicine Institute, led by Matt Might, PhD, Professor of Medicine and Director of the Precision Medicine Institute, immediately moved into action leveraging substantial capabilities and tools: from artificial intelligence to computational genomics methods and models, reports Bob Shepard from UAB News.
The director commented, “One of our strengths is to use our trained analysts and artificial intelligence tools to look for FD...
Note: If you need assistance with your subscription or would like to discuss a corporate subscription for more than 10 employees please contact us or use the chat (bottom right).